Mo1561 GUT SELECTIVE BIOLOGIC, VEDOLIZUMAB, IS ASSOCIATED WITH LOWER RATES OF LIVER RELATED COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH CIRRHOSIS-A NATIONWIDE ANALYSIS
Mo1561 GUT SELECTIVE BIOLOGIC, VEDOLIZUMAB, IS ASSOCIATED WITH LOWER RATES OF LIVER RELATED COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH CIRRHOSIS-A NATIONWIDE ANALYSIS
